NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia’s MammaPrint Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data
ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for Read More
Agendia’s MammaPrint recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update
IRVINE, CA and AMSTERDAM – 6 July 2017 - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics announces that the 15th St. Gallen International Breast Cancer Guidelines recently published in Annals Read More
MammaPrint Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment
Retrospective analysis of patient samples from the prospective, randomized Stockholm Tamoxifen Trial demonstrates clinical utility of MammaPrint in identifying breast cancer patients with exceedingly low likelihood for late recurrence at 20-years MammaPrint Late Recurrence (20yr) Read More
Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients
A multi-center trial demonstrated that MammaPrint identified 30% more low risk patients than the 21-gene test. MammaPrint Low Risk patients had an excellent 98.9% 5-year metastasis free survival Data from the I-SPY 2 trial reported Read More
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif., IRVINE Calif., June 2, 2017-Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today Read More
Agendia’s MammaPrint Now Included in Blue Shield of California Coverage for Breast Cancer Patients
IRVINE, CA and AMSTERDAM – 1 June 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that Blue Shield of California has updated its Medical Policy 2.04.36 Assays Read More
Agendia’s MammaPrint Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands
IRVINE, CA and AMSTERDAM – 2 May 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that First Coast Service Options Inc. (“First Coast”), the Medicare contractor for Read More
